Mycobacterial (Skin) Infections

Naafs, Bernard; Hees, C.L.M. van; Ingen, Jakko van

doi:10.1007/978-3-319-39424-4_6

Cited by 3 publications

(2 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in our experience severe reactions need high dose steroids (60–120 mg) for a short period, diminishing to zero in a month or less. A new attack should be treated in the same way . This way of treatment is not yet generally accepted.…”

Section: Reactionsmentioning

confidence: 99%

Position statement: LEPROSY: Diagnosis, treatment and follow‐up

Belachew

Naafs

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Leprosy or Hansen's disease is a chronic infection caused by Mycobacterium leprae (M. leprae) or Mycobacterium lepromatosis (M. lepromatosis). In Europe, most of the leprosy cases are imported. However, occasionally a case is diagnosed in one of the old endemic foci. Leprosy is often not suspected because it is no longer emphasized in the medical curricula. Attention shifted from leprosy to tuberculosis and human immunodeficiency virus infections in the late 20th century, whereby the WHO leprosy programme was toned down in the conviction that leprosy was all but eliminated. The result of unawareness is a harmful doctor's delay. Material and methods This paper focusses on clinical diagnosis, complications and treatment based on literature and experience. Results It mentions the value of laboratory tests in classification, follow‐up and detection of relapses. It discusses the etiopathology. Conclusion This is a position statement.

show abstract

Section: Reactionsmentioning

confidence: 99%

Position statement: LEPROSY: Diagnosis, treatment and follow‐up

Belachew

Naafs

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…In most cases, patients develop immunity by the natural course of the disease, and the infection is eliminated with a defined scare. Despite no complete elimination of the infection, treatment accelerates the healing process but with a compromised immunity response (5,6). All patients with urban cutaneous leishmaniasis (ACL), which patients transmit, should be treated to prevent the spread of the disease.…”

Section: Introductionmentioning

confidence: 99%

Lifetime and Point Prevalence of Cutaneous Leishmaniasis in the South of Iran

Izadi¹,

Barjoei²,

Pourrezaei³

et al. 2023

J Health Rep Technol

View full text Add to dashboard Cite

Background: Cutaneous Leishmaniasis (CL) is a public health problem in many countries in Asia. Fars province in the south of Iran is an area with endemic CL. Objectives: This study aimed to estimate CL’s lifetime and point prevalence in the Fars province’s general population. Methods: This cross-sectional study was conducted on 11779 participants living in Marvdasht, the second largest county of Fars province, Iran, in 2019 to estimate CL’s lifetime and point prevalence. In total, 59 urban and 55 rural clusters (with 30 households per cluster) were randomly selected. Door-to-door interviews were conducted by trained nurses to collect the required data. Results: The point prevalence was estimated at 3.56 (95% confidence interval: 2.6-4.8) per 1000 population. The lifetime prevalence of CL was 8.48 (95% confidence interval:7.99-9.00) per 100 population. There was no difference between urban and rural areas and gender regarding fresh or old scars, and CL scares (P ≤ 0.05 for all). Conclusions: Based on the results, Marvdasht in Fars province was the hyperendemic area for CL. Since the lifetime prevalence of CL in Marvdasht is almost 8%, 89% of the people of this city are at risk of contracting Leishmania. As a result, more public health interventions are needed to control the CL epidemic in Marvdasht.

show abstract

Mycobacterioses in Pigmented Ethnic Skin

Dassoni

Naafs²

2018

Pigmented Ethnic Skin and Imported Dermatoses

View full text Add to dashboard Cite

Mycobacterial (Skin) Infections

Cited by 3 publications

References 150 publications

Position statement: LEPROSY: Diagnosis, treatment and follow‐up

Position statement: LEPROSY: Diagnosis, treatment and follow‐up

Lifetime and Point Prevalence of Cutaneous Leishmaniasis in the South of Iran

Mycobacterioses in Pigmented Ethnic Skin

Contact Info

Product

Resources

About